3Masuda S,Nagao M,Takahata K,et al.Functional erythropoietin receptor of the cells with neural characteristics:Comparison with receptor properties of erythroid cells.J Biol Chem,1993,268(15):11208-11216.
5Patel NS,Sharpies EJ,Cuzzocrea S,et al.Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo.Kidney Int,2004,66 (3):983-989.
6Bahlmann FH,Song R,Boehm SM,et al.Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure.Circulation,2004,110(8):1006-1012.
7Kang DH.Park EY,Yu ES,et al.Renoprotective effect of erythropoietin (EPO):Possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney.Kidney Int,2005,67(5):1683.
9Toba H,Sawai N,Morishita M,et al.Chronic treatment with recombinant human eiythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat.Eur J Pharmacol,2009,612(1-3):106-114.
10Gong H,Wang W,Kwon TH,et al.EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney.Kidney Int,2004,66(2):683-695.
3Vasavada N, Agarwal R. Role of oxidative stress in diabetic nephropathy. Adv Chronic Kidney Dis, 2005, 12: 146-154.
4Prabhakar S, Starnes J, Shi S, et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol, 2007, 18: 2945-2952.
5Krantz SB. Erythropoietin. Blood, 1991, 77: 419-434.
6Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology (Carlton), 2006, 11: 306-312.
7Bahhnann FH, de Groot K, Hailer H, et al. Erythropoietin: is it more than correcting anaemia? Nephrol Dial Transplant, 2004, 19: 20-22.
8Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin oi: erythropoietin protects against ischaemic acute renal injury and failure. Kidney lnt, 2006, 69: 1806-1813.
9Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA, 2004, 101: 823-828.
10Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting etythropoietin analogue darbepoetin alpha persis-tently activates endothelial Akt and attenuates progressive organfailure. Circulation, 2004, 110: 1006-1012.
